Gilead Sciences (GILD) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Gilead Sciences (GILD) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
168.07% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-52.40% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-45.93% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
1,078.32% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
- |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
-9.84% |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
32.85% |
| Date | Value |
|---|
| Mar 31, 2026 |
53.69% |
| Dec 31, 2025 |
41.86% |
| Sep 30, 2025 |
143.58% |
| Jun 30, 2025 |
21.42% |
| Mar 31, 2025 |
131.53% |
| Dec 31, 2024 |
25.85% |
| Sep 30, 2024 |
-42.31% |
| Jun 30, 2024 |
55.44% |
| Mar 31, 2024 |
-523.88% |
| Dec 31, 2023 |
-13.29% |
| Sep 30, 2023 |
21.61% |
| Jun 30, 2023 |
-8.46% |
| Mar 31, 2023 |
8,100.00% |
| Dec 31, 2022 |
334.31% |
| Sep 30, 2022 |
-30.94% |
| Jun 30, 2022 |
-24.83% |
| Mar 31, 2022 |
-99.30% |
| Dec 31, 2021 |
-75.34% |
| Sep 30, 2021 |
690.83% |
| Jun 30, 2021 |
143.63% |
